Inovio Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Inovio Pharmaceuticals has a total shareholder equity of $94.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $129.1M and $34.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$105.61m |
| Equity | US$94.44m |
| Total liabilities | US$34.67m |
| Total assets | US$129.11m |
Recent financial health updates
Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?
Oct 23
Inovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?
Mar 21Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt
Sep 24Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt
Jun 11Recent updates
Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates
May 15Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates
May 13Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?
Oct 23Inovio reports positive phase 1/2 results for recurrent respiratory papillomatosis drug
Oct 13Inovio Pharmaceuticals: Long On Promise, Short On Results
Sep 27Inovio Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $0.78M beats by $0.26M
Aug 09Inovio: After All These Years
Jul 19Inovio: Long-Term Biotech To Own With Several Catalysts Expected In 2022
Apr 15Inovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?
Mar 21Inovio Undervalued On Potential 2022 Catalyst
Jan 26Calculating The Intrinsic Value Of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
Dec 31Inovio Pharmaceuticals: Forget The COVID Pump, And Keep Your Eye On The Oncology Side
Nov 18Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt
Sep 24Inovio: Simply Cannot Be Ignored
Sep 03Inovio Has 4 Sources Of Potential Value
Jun 23Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt
Jun 11Inovio stock trades higher defying insider sale
Jun 07Financial Position Analysis
Short Term Liabilities: INO's short term assets ($111.7M) exceed its short term liabilities ($23.4M).
Long Term Liabilities: INO's short term assets ($111.7M) exceed its long term liabilities ($11.3M).
Debt to Equity History and Analysis
Debt Level: INO is debt free.
Reducing Debt: INO has no debt compared to 5 years ago when its debt to equity ratio was 74.8%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: INO has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: INO has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 13.8% each year.